Wednesday, 25 June 2014

Vertex results from TRAFFIC/TRANSPORT

Yesterday Vertex announced preliminary results from the Phase 3 trial of Lumacaftor in combination with Ivacaftor in patients aged 12 and over with two copies of the F508del mutation. The trial involved 1,100 patients at almost 200 sites across the world.

For me, the most interesting points were:
  • Mean absolute change in % predicted FEV1 was approx. 3% and mean relative change in % predicted FEV1 was approx. 5% (on the basis of pooled data). That means if a patient’s baseline FEV1 was 60%, on average they would have seen an increase to 63%. While this is less dramatic than the effect seen in G551Ds on Ivacaftor monotherapy, it was statistically significant and, for many people with CF, each % point maintained is important;
  • Statistically significant increase in Body Mass Index (BMI)
  • Delayed time to first pulmonary exacerbation;
  • 30-39% reduction in pulmonary exacerbations (depending on the dose);
  • 39-61% reduction in exacerbations requiring hospitalisation;
  • 45-56% reduction in exacerbations requiring intravenous antibiotics;
  • Some people on the trial had baseline FEV1 below 40%. While the eligibility criteria was 40%, some dipped below this threshold in the period between screening and first drug. These patients seem to have responded just as well as those with higher baseline FEV1;
  • Approx. 90% of people on the trial decided to rollover into the open label extension including those who had been taking placebo during the trial period. This says something about how the drug made patients feel in themselves; and
  • The Quality of Life questionnaire (which is validated by regulators) failed to show any improvement in quality of life. This seems at odds with the data above and, to me, suggests the instrument is not tuned into the things that really matter to patients. Perhaps there is a need to develop a new way of measuring quality of life. It would be a long process to get a new instrument validated but it could pay dividends and it something that could be done in partnership with patients and families.

Vertex now plans to submit the data by the end of 2014 to regulators in the US and EU in order to get a marketing authorisation. If approval is given, they will then embark on the process of securing reimbursement. All this will take time and there are risks at every stage.

While this combination therapy does not appear to be transformational for those with two copies of F508del in the way Ivacaftor has been shown to be in many G551Ds, it is exciting and provides a solid stepping stone for further development by Vertex and others. It is probably more of a bridge to the future than a home run in itself. It should reassure researchers that this problem is one that can be solved.

It is surprising that the effect on exacerbations was so dramatic given the modest effect on FEV1.

Here’s why I think reducing exacerbations is more important than increasing FEV1:

FEV1 is hard to measure in a reliable way even in adults. It is dependent on technique and it can be affected by lots of factors unrelated to underlying lung function. It becomes less reliable as lung function deteriorates which is, arguably, when we most need a reliable measure.

If you ask someone with CF how they feel, they are unlikely to talk about FEV1. FEV1 is not something patients feel or necessarily perceive.

It is well established that more exacerbations lead to worse health outcomes. The mechanism is clear and cruel - most people with CF die of lung failure, every exacerbation can cause incremental lung damage that is irreversible so moving us a little step closer to lung failure. If we think of it like a staircase down to lung failure, we obviously want the distance between each step to be as long as possible and we want each step to be as shallow as possible. Weight gain directly helps here too. Just breathing and keeping permanently resident bugs at bay takes a lot of energy for us. The more energy we have in reserve the better able we are to fight off infections before they flare-up into exacerbations (or the better we are able to minimise the severity of the exacerbations that do hit us). Therefore, weight gain can help extend the distance between steps and minimise the depth of the steps by creating resilience. 

Obviously exacerbations are disruptive to life so there is a clear and immediate quality of life impact for patients and families.

Personally, I wish I had known when I was younger that exacerbations tend to cause irreversible lung damage and knock you down a step. When I was a teenager and relatively healthy, I hated doing all my treatments particularly nebulisers and airway clearance. I sometimes used to think, “I’m fine and busy with my life. I won’t bother doing all my treatments. I'll wait until I get sick and then go to the hospital to get fixed". I didn’t think I was losing anything but I really was.


Traditionally FEV1 is seen as the gold standard test for measuring the effects of new therapies. There may well be a case to review that now. The therapeutic pipeline for people with CF is stronger than ever before and these results will help underpin further development.

Monday, 10 March 2014

Travel Insurance and Oxygen

I have spent many hours researching travel insurance and travel oxygen. I just spoke to Insurance Choice and it feels like a breakthrough. 


They are an arranger not an underwriter. She said the best underwriter by far for CF is "Fit for Travel". They are the only company who write their own medical questions and this makes them more flexible. She took my details and then went through their process with me. The questions were thorough but more sensible than normal. It seemed like they understand CF more than others! 

They have a website but there's not much on it so I recommend just calling.

Tel: 0844 5577980 (ask for Sophie)

I have found in the past that the number of "unplanned" admissions I have had in the last year or two years has been a blocker. I usually go in 2 or 3 times a year. I go in when I am sick not a pre-planned basis. These guys ask about all admissions in the last two years (not just unplanned ones i.e. pre-emptive pre-planned ones count). In the last 2 years I have been in 5 times. This was not a blocker.

I also have CFRD and I need oxygen on the plane, with exercise and overnight. This was not a blocker.

I am thinking about going to Greece for 2 weeks in April. They quoted me £225. She said it would be similar anywhere in the EU.This includes £5,000 cancellation cover and £10m emergency including repatriation and legal.

After getting the quote, I had a decent chat with her. She said the question about admissions in the last two years has two answers "0-9" or "more than 9" i.e. if I had been in 9 times it would not make that much difference. If more than 9 admissions, they may still cover but it will cost more. She said she recently arranged cover for a lady with CF in a similar situation to me who is going to the US. The quote for her was £650.  

I need to take oxygen abroad. I use 2 litres/min pulsed when I do exercise and I use 2 litres/min continous overnight. I will use 2 litres/min on the plan since the flight will be more than 2 hours. I tend not to need O2 for shorter flights. Air Liquide provide my O2 at home and they are pretty good about travel within the UK but they will not help abroad. If you have an EHIC you can arrange O2 locally within the EU but it can take a long time to organise, there is sometimes a cost and I'm told the equipment is not always as good as it is here. I called British Lung Foundation and they gave me a list of companies that will rent out portable O2 equipment to take abroad. This is going to cost me about about £400 for 2 weeks. I tried PureO2 (08707 120202), 10sMedical (0121 355 6555) and Intermedical (0800 0282194) and they are all similar but I would recommend PureO2 because they seem a little bit more professional and responsive. I can use this equipment on the plane too but if I go with an airline that provides it free I might use that facility.

The British Lung Foundation website is good for general information and the people on the helpline are very helpful:


There is also some good inforamtion and advice on the Cystic Fibrosis Trust website:


I hope it is useful for others with CF. Where there's a will there's a way! 

Monday, 26 August 2013

Which CFTR mutations actually cause CF?


A recent study sheds new light on which of the 1,900 plus known mutations of the CFTR gene actually cause cystic fibrosis (CF) and which do not. The study is called "Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene" and it was published on 25 August 2013 in Nature Genetics. The results have important implications for family planning and drug development although this work is ongoing and part of a bigger project aiming to characterize all known CFTR mutations. Researchers analysed genetic information from nearly 40,000 CF patients to find out which of the 1,900 mutations cause CF and which are benign. Their findings increased the number of known CF-causing mutations from 22 to 127. Prior to this, more than 25% of couples in which both partners were found to carry a mutation on the CFTR gene could have no way of telling whether their mutations could actually cause CF in their offspring. As a result of this study, that is reduced to 9%. The work provides some interesting clues for drug development too. By looking at the differences in severity of disease caused by changes in CFTR associated with different genotypes, the researchers have a better idea of the potential efficacy of drugs which achieve the same changes in CFTR.

I emailed some questions to Dr. Patrick Sosnay, co-author of the study and assistant professor of pulmonary and critical care at Johns Hopkins University. 


How did you do this study?

"We collected CF patients and parents from around the world (mostly N. America and Europe) and looked at the mutations they had. We then looked at each of these mutations to tell for sure if they caused CF. We looked at the clinical outcomes of patients that had those mutations (assuming the higher their sweat chloride, the more likely the mutation was truly a CF causing mutation); we looked at how the mutation behaved in experiments (the less it behaved like the non-mutated or "wild-type" CFTR, the more likely it was truly a CF causing mutation), and we looked at how often it was seen in people with CF, vs. carriers, vs. the general population."

What is the relevance of the results?

"We have better defined the range that can be seen with the 159 most seen CF mutations. Some always cause CF, some cause CF some of the time, and some we do not think cause CF. Obviously, because it is a recessive disease a patient has to have mutations on both copies of CFTR they inherit."

What are the implications of this data for family planning?

"This will help genetic counselling in that we will have a better idea what the most likely consequence of a mutation is. People having genetic testing done before this study were more likely to get back a CF mutation that we did not know how to interpret. They would be told – you have a mutation in CFTR, we do not know if it causes CF or not. There are still many mutations out there that are uncharacterized, but we have chipped away at some of the more common ones."

What are the implications of this data for drug development?

"This information will be used by scientists studying therapies to group mutations according to their functional consequences. We also hope to learn more about what contribution CFTR genotype makes to making CF mild or severe."

Is this project continuing and what is the ultimate goal?

"This work is continuing. For every mutation that has ever been seen in CFTR, we want to be able to say: does it cause CF, if so what drugs could be used against it?"

Here is a link to the study in Nature GeneticsDefining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene


Monday, 29 April 2013

Speech to CF Trust Scientific Conference 2013


29 April 2013 at The Wellcome Trust, London.

"Good evening, everyone. It’s an honour to be able to speak to you tonight. It’s a bit overwhelming actually. I feel a bit like a kid speaking to a room full of Father Christmases.

I want you all to imagine – you can close your eyes if you like - I want each of you to imagine you’re in a little wooden boat floating in the middle of the ocean. As you bob up and down, you feel the sun on your back, you can hear the distant sound of birds and you can smell the sea air. Sounds pretty nice. But there’s a problem. The boat is full of holes and water is gushing in. There are sharks. All you have (to bale out the water) is a tea spoon. You spend most of your time baling with your tea spoon trying to stay afloat. You do it all day. You go to sleep, you wake up in a boat full of water and you start baling again. It is exhausting and relentless. You need a bigger spoon. Better yet, you need to find a way to plug the holes. That’s what CF feels like to me.  It’s a fight against drowning in my own mucus.

I was diagnosed in 1978 at the age of 3. When I was 14 my consultant told me I’d probably need a heart and lung transplant in my early twenties and that I’d be lucky to live beyond 25. This [Spoon 1] was standard of care in those days. Well my heart and lungs are still original and I’m still here at 37. During that time, we’ve seen the development of better spoons - nebulised antibiotics like TOBI [Spoon 2], mucus busting therapies like Pulmozyme and Hypertonic Saline; and more effective airway clearance techniques [Spoon 3]. These all resulted from research and I might not be here without them. I want this [Spoon 4] but I have this [Spoon 3]. Kalydeco is a bit different – it’s plugging holes - but I’ll come on to that.



New treatments are exciting and important but, actually, I think it’s just as important to develop better tools to manage symptoms and figure out how to use the tools we already have in a more effective way. 

So I want to talk about three things: the therapeutic portfolio, clinical trials and adherence.

THERAPEUTIC PORTFOLIO

Vertex’s new drug Kalydeco is a small molecule with big implications. This little blue pill is changing the lives of the 4% of CF patients with the G55-1D mutation. Trials to see if Kalydeco works for other similar mutations are underway. Phase 2 data released by Vertex on April 18th, in a press release, has bolstered hopes that Kalydeco might work in combination with various other small molecules to treat a much broader range of CF patients including people like me with the most common delta F508 mutation.

This is incredible – when I read the blogs and hear the stories of people on Kalydeco – it is mind-blowing. It brings a tear to my eye. But there’s a long way to go from Kalydeco to a Kalydeco-like therapy for all 1,800 mutations and it is important to remember that, even for G55-1Ds, Kalydeco is not a cure. These people still have CF.

They still need to do all their other treatments. They still have chronic infections and exacerbations that mean they need IVs - but not as often. They are significantly better, able to do more stuff without getting breathless, put on proper weight, bounce back faster from exacerbations and generally far more resilient. Those on Kalydeco seem able to shake off a cold without it turning into an exacerbation – in other words two weeks in hospital becomes 2 days off work. I hear about patients with G55-1D who’ve come off the transplant list or who no longer need a wheelchair or oxygen therapy. They can go back to work or perhaps go on holiday. Maybe their parents no longer need to act as such full-time carers so they can go back to work or have a more normal life too. These patients are able to think about and plan for the future in an entirely new way. The trajectory of their disease has changed. It is hard to explain because the way CF affects patients and families is so complex - and maybe we need to find better ways of articulating the true value of these medicines - but this is a profound leap forward and it is exciting to think the same approach may help those with other mutations.

For young children whose lungs and other organs are not yet damaged, drugs like Kalydeco could be very close to a cure. For older ones whose organs have been damaged, Kalydeco might freeze the disease but it won’t reverse damage already done. So even if there was a Kalydeco-like treatment for all mutations, symptom-management tools will still be needed. In fact, they may well be needed more than ever because people with CF will be living longer. 

CF is a complex disease and it seems likely that complex combinations of small molecules and other kinds of therapies will be needed. Lots of money is going into small molecule CFTR modulators. As a patient, I worry we are putting all our eggs in one basket. It may not work. It may half work. I think it’s vital for the CF community to nurture some alternative approaches and facilitate some alternative science. I think we need to hedge our bets.

The CF Trust has always been committed to research and I think this commitment is more important now than ever before. Of course, the Trust established and funded the Gene Therapy Consortium and this is pioneering new techniques. While even this is not a “cure” as such it may turn out to be just as important as small molecules or more important. This would not have been possible without the Trust’s funding and the tenacity of those involved. I hope the Trust can continue to support this programme as part of a broader portfolio.

It’s essential that the CF Trust works in conjunction with the CF Foundation and others to achieve a diversified portfolio of therapeutic options. We need to go after better spoons - more effective symptom-management tools (particularly those which can reduce inflammation or neutralise Pseudomonas and other lethal bugs) – as well as looking for new ways to rescue chloride channel function - to plug the holes.

CLINICAL TRIALS

In the UK, about 10% of CF patients have participated in a clinical trial. We need to do more. We make it far too difficult for sponsors to do trials. We need to make it easier because we’re all losing out.

Studies show that simply taking part in a trial can improve a patient’s health and that is irrespective of whether they receive the active drug or placebo; and irrespective of whether the trial has a positive or a negative result. It is not just about being an altruistic guinea pig, it’s about direct benefits (for patients, clinicians and hospitals) and establishing a more positive culture that forces everyone to raise their game and not to settle.

This means making sure that, when there is a new drug, our patients have the opportunity to take part in clinical trials but it also means doing more trials to make sure we are using the tools we already have as effectively as we can.

Trials, funded by the CF Trust, like the TOPIC study on once vs three times a day aminoglycosides, have resulted in significant improvements in care. In some cases they have allowed treatments to be simplified and ineffective ones to be stopped. These kinds of trials are really important and we need to do more.

It also makes sense to get patients and parents involved in clinical research at the design stage. After all, clinicians only see patients and collect data when the patient comes to the clinic - or in hospital. It is the patients and their families who live with CF day-in/day-out. We are the only ones with a 360 degree view. Why can’t we use this experience, and data collected at home, systematically to inform clinical trials, and clinical practice more generally, to make sure we’re asking the right questions and working towards the outcomes that are most relevant to patients in their daily lives? Internet technology has made this easy to do and, if our aim is to improve real world outcomes, I think we have no choice but to embrace it. That’s why I’m really excited by initiatives like CFUnite (backed by The Wellcome Trust), Cochrane and the James Lind Alliance; and the CF Trust’s commitment today to do more to facilitate patient involvement in this more strategic aspect of clinical trials.   

ADHERENCE

This is a big deal and we need to talk about it more. One of the most challenging aspects of having CF, for me, is the heavy burden of daily treatment. Every day I take about 40 pills, 7 nebulisers, a saline nasal rinse, 4 inhalers and do 2 or 3 injections, blood sugar tests and two sessions of self-administered physio. I spend a lot of time washing and sterilising nebuliser equipment. All this takes 3 hours on a good day and up to 4 hours when I am less well. This is my normal. When I get an exacerbation I typically need a 14 day course of hospitalised IV antibiotics. This tends to happen 2 or 3 times a year. I am lucky, for many it is much worse.

So CF adherence is not just popping pills - this is real work, it is difficult and it can be exhausting. You can never take a day off. Some of the treatments are unpleasant - they require a lot of effort and willpower. It becomes much harder to get all your treatments done, and it takes longer, when you’re not feeling so well which is, of course, exactly when you need them most. It is easy to feel overwhelmed with treatments. It’s hard to find a balance. It is hard to create reliable windows for work, family and friends; and for all the other things you have to do to get by in life. 

So we need to find ways to reduce the burden of treatment. Something which saves an hour a day and can be done anywhere is going to have a dramatic impact on quality of life and, I think, adherence. Clearly there is a link between poor adherence and hospitalisation. We do too much fire-fighting and we need to focus more on prevention. We need to recognise the value of prevention.

It may mean simplifying treatments; developing a pill or inhaler to replace a nebuliser (more things like Bronchitol, TOBI Podhaler and Colobreathe); or more creative things, perhaps bringing in some sports psychology techniques; or web-based platforms or smartphone apps that help to manage and motivate or allow people to track their progress or even just talk to someone who’s in the same situation (because don’t forget we can’t meet up due to the risk of cross-infection). This kind of thing could help people live a fuller life, stay healthier, reduce exacerbations and keep them out of hospital. This is worth doing, big time, and I think it’s great that the Trust has highlighted adherence and reducing the overall burden of treatment as key research priorities. It’s a simple relation: reduce the burden, improve adherence; reduce exacerbations.

So here’s what I want you to take away:

The CF Foundation and Vertex have blazed a regulatory trail, given us new tools, shown Pharma that CF is a real market, shown everyone what can be achieved when Pharma works with a patient group. They have delivered a transformative drug for a very small sub-population of CF. I see this as injecting oxygen into the CF research environment. It’s woken people up. It’s like our Big Bang. We need to capitalise. We need to use it to our advantage. That’s why the Trust’s new strategy launch is perfectly timed. It provides a great scientific map but it also sends a clear signal of the Trust’s intent to collaborate with new partners, in new ways and to make resources available to help everyone in the CF community convert their ideas into new therapeutic tools.

And as Yoda said: “do or do not, there is no try".

Thank you." 

Saturday, 2 March 2013

EURORDIS: Sounds Like a Plan, Yann!

Last week I was invited by Yann Le Cam, CEO of EURORDIS, to some important rare disease policy events in Brussels. These events brought together a very passionate community of people including EC officials, MEPs, representatives from the European Medicines Agency, national officials, Pharma, researchers, patient groups and others. All these people are working on ways to improve access to orphan medicines and better treatment options for people in the EU with rare diseases.  I was really impressed with the way people from across the spectrum were all working together and making a difference. It felt like there was a great sense of camaraderie and real solidarity with everyone uniting against "the system" which I found surprising and inspiring. I found the experience genuinely moving and it was great to have the chance to meet so many smart people working in such an important and relevant area. 

Based on my recent experience of the issues with getting Vertex’s Kalydeco to patients in need, I was keen to go along and find out what is being done at the EU level to address some of the problems. As I see it, there are problems at almost every point of the drug development cycle from clinical trial design and marketing authorisation through to payers' cost-effectiveness reviews and post-marketing data collection. 

Why does it take so long after EMA Marketing Authorisation for drugs to reach patients? Why aren’t new treatments compared to current standard of care? Why wasn’t Bronchitol tested against hypertonic saline? Why do regulators insist new antibiotics are tested against placebo when hardly anyone with CF is not on at least one antibiotic? Why don’t NICE and other payers take proper account of quality of life, adherence and the effects of a new treatment on patients’ family members? Why don’t people get angry about their governments wasting hundreds of millions on branded drugs when therapeutically-equivalent, lower-cost generics will do the same job? Why do people object to paying high prices for genuine innovation? Why does it cost so much to bring a new medicine to market? These sorts of issues are common to all rare diseases and we stand a better chance of changing things if Pharma, patient groups, clinicians and others work together as everyone’s interest is served by improving access to rare disease medicines and the real problem is often government or State-controlled healthcare providers and health insurance systems.

A rare disease is any disease that affects a small percentage of the population. The European Union considers a disease as rare when it affects fewer than 1 in 2,000 citizens. Rare diseases are frequently chronic, progressive, degenerative and often life-threatening. Over 6,000 different rare diseases have been identified to date and 30 million people in Europe are affected. Rare diseases are also known as orphan diseases because they have traditionally been abandoned by governments and drug companies who cannot justify the investment in researching new treatments for such small groups of people. Despite their vast overall number, rare disease patients frequently lack access to diagnosis, treatment and the benefits of research.

EURORDIS is a non-governmental patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe. EURORDIS represents 561 rare disease organisations in 51 countries (including 25 EU Member States) covering more than 4,000 rare diseases.

In terms of EU rare disease policy, EURORDIS is clearly the prime mover and they have built a collaborative community of key stakeholders to shape and implement policy at the highest level. Yann Le Cam and his team have built this community and really drive it forward in a way that benefits patients while keeping key stakeholders on board. That is a wonderful thing. Overall I had a fascinating time over the Tuesday and Wednesday in Brussels and I hope to be able to build on my relationship with EURORDIS and the rare disease community as a whole.

The Big Picture 

There seems to be a realisation, in this community at least, that science is progressing in such a way that medicine is increasingly able to address whole new areas of disease and treatments are becoming more personalised. Treatments which only work on a small number of people are very expensive. We are moving into a world of ultra-orphan indications. It is clear that we will not be able to afford to pay for everything. So everyone is thinking very hard about what is funded and how to change the way the system is funded to maximise the benefit. In particular, there is increasing concern about the fact healthcare in the EU is largely “pay-as-you-go”/ unfunded in contrast to pensions which are generally funded, albeit poorly. Economists all agree that healthcare spending is going to become a far more significant proportion of total public expenditure in the future. Social/welfare commitments are seen as fundamental to the EU model so we had better find a way of paying for it! There is an increasing realisation that better healthcare would allow people to work more and for longer so spending in health will take pressure off social/welfare budgets. There should be more “fluidity” between health and welfare budgets. People, in this community at least, are starting to think about this in a more integrated way. 

It turns out that Pharma may be prepared to negotiate caps on general pharmaceutical budgets if it means more spending on orphan products. This is seen as a “re-distribution towards innovation” and something to be welcomed.  Similarly, everyone involved in the rare disease community should help to identify and highlight inefficiencies / waste in healthcare systems so as to force their governments to make savings where possible and create a greater degree of “headroom for innovation”.

There was a lot of talk of the need to mobilise “civil society” to force change. While EURORDIS is seen as a very effective voice for rare diseases in the Brussels village, there is an urgent requirement to mobilise local patient groups and other grass roots activity.

Tuesday 26th
Seminar on Faster Access to Medicines for Rare Disease Patients: “The Transparency Directive”

Why is it important? 

This measure aims to speed up the process of Health Technology Assessments and Pricing and Reimbursement decisions. It aims to remove duplication of work between the EMA and HTAs in individual countries and to bring greater transparency.

There is already a transparency directive in place but it is “soft” and poorly implemented and it is no longer compatible with the dynamics of the pharmaceutical market, particularly in relation to generics. The “new” Transparency Directive aims to bring greater transparency to the Pricing & Reimbursement (“P&R”) procedures in each Member State (e.g. the HTA reviews carried out by groups equivalent to NICE). According to EU officials, it is widely known that officials in several Member States are currently bribed to delay the entry of generics. A major objective is to stamp out corruption and save money for payers, particularly by accelerating generic substitution.  It is estimated that “late” transition to generics costs the EU more than €1bn per annum. Saving money for healthcare budgets in this way would release funds for the more expensive orphan drugs that will be an increasing feature of the market going forward.

The three elements are:

1. Time Limits: 180 days hard deadline for all P&R decisions but much shorter (30 days) for generics;
2. Statement of Reasons: national authorities must provide verifiable grounds for decisions; and
3. Remedies: legal remedies to be made available to applicants in the event of adverse decision.

The Directive also seeks to bring a clear separation of the Marketing Authorisation (MA) process and P&R processes in Member States and to eliminate duplication of work as far as possible given the fundamental rights of Member States to organise and fund their own healthcare systems (Article 168/7 Treaty on the Functioning of the European Union). The Directive aims to stop competent authorities in Member States from re-assessing aspects that have already been thoroughly assessed by the EMA as part of the MA process; to stop them “re-opening the science” or even re-evaluating the orphan designation.

Richard BergstrÖm, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) talked about how the pharma market had changed. Traditionally, pharma would consider their job done when their products got MA. Now there is a “4th hurdle” – the Pricing & Reimbursement hurdle. The real issue at the moment is access to medicines and that means who is going to pay, how much and when. The Transparency Directive is a necessary and important technical/procedural measure but it does not address the key issue. He said the current system in the EU is a mess and it doesn’t work for patients, payers or Pharma. It is too fragmented and this makes it very difficult for pharma. Pharma is open to talking about price and doing deals but there is currently nobody to call. For regulatory matters it is easy, you just go to the EMA. For P&R matters, there is no place to go. There needs to be a “front door” where people can go and have a sensible discussion.

It was great to listen to Richard BergstrÖm talk. He has an ability to cut through the procedural language and bureaucratic obstacles to get to the big issues, join all the dots together and say what really matters. It is incredibly refreshing to hear such integrated thinking and, as a patient, I found it extremely encouraging. It is mad that you get  labelled as a shill for the Pharma industry if you criticise government and market inefficiency when in fact your only objective is to get medicines to patients faster and encourage Pharma to take the risk of developing new treatments. The media in the UK is extremely "tabloid" in its approach to these issues and it is very unhelpful. I always feel politicians try to deflect attention from their own failings by seeking to paint Pharma as the bad guys and the media lap this up as it plays so neatly into the anti-capitalist narrative. Why don't people get more angry about their governments wasting hundreds of millions of Euros on branded drugs when generics will do just as well? Yet we balk at paying a decent price for genuine innovation (even though the total amounts represent a fraction of the wastage elsewhere). BergstrÖm  made a strong point when he said society wanted a "tap" of new drugs but they did not want to pay for the pipeline to supply the tap. I got a powerful sense that BergstrÖm  is an agent for positive change and I wish there were more people like him. 

Antonyia Parvanova, the brilliant outspoken MEP who is sponsoring the Transparency Directive and Cristian Busoi MEP who is also instrumental in this legislation, talked about an ambition to build a common market in pharmaceutical products - it is not one of the product categories for which a common market has been established under EU law. They see the Transparency Directive as critical to bringing clarity and transparency to the HTA/reimbursement process, eliminating corruption and saving substantial amounts of money by accelerating the transition to generics and getting new medicines to market faster. 

The emphasis is on showing the value / savings available to all parties rather than sanctions. Payers will save substantial amounts of money, pharma will be better able to invest and patients will get better access to treatments. 

There is a great deal of work going on around the total burden of rare diseases (i.e. health, welfare and social costs) so that we can see the true value of new medicines.

In terms of broader EC policy, Jaroslaw Waligora (Policy Officer, DG Health and Consumers) talked about the importance of patient registries in rare diseases. These are seen as crucial to effective research going forward. Currently there are hundreds of separate rare disease registries around the EU, not compatible with each other and hard to access. They need to be easier to aggregate and analyse. There are some initiatives that are helping (e.g. EPIRAR, EJA Joint Action, RD Connect) and there is a new EC initiative to establish a common platform (IT tools, software). This aims to bring greater compatibility, enable better data analysis and facilitate clinical trials. The disease-specific “European Reference Networks” made up of “Centres of Expertise” are an important part of this too.

Several audience members raised concerns about the Data Protection Directive and made the point that it raises barriers to patient registries which are so crucial to rare disease research. EURORDIS has released a clear statement on this issue (in defence of patient registries) and others with an interest in rare disease research should voice their concerns too. This issue is particularly important to CF and if patient registries are made impossible to operate as a result of the Data Protection Directive, as proposed, it will be a serious barrier to the development of new treatments.

There were about 100 people in the room including EC officials, MEPs, other officials from Member States, people from EMA, Eurordis, Pharma, Researchers and Patient Groups. The meeting was broadcast live over the web.

EURORDIS “Black Pearl” Gala Dinner 2013

This was a fundraising event with around 300 people in attendance. The aim was to explain the achievements to date of EURORDIS and the rare disease community but also to highlight the massive challenges ahead and the need for greater cross-border co-operation. They played some incredibly moving videos showing real life stories of people with rare diseases. Awards were presented to certain individuals and companies who had made a significant difference to the lives of those with rare diseases.

EURORDIS Awards 2013

Policy Maker Award: FranÇoise Grossetête, MEP
European Rare Disease Leadership Award: Dr Ruxandra Draghia-Akli
Volunteer Award: Lesley Greene
Scientific Award: Dr Ségolène Ayme
Patient Organisation Award: AlstrÖm UK
Company Awards: Celgene, Prosensa, Genzyme
Media Award: Andrew Jack
Lifetime Achievement Award: Former First Lady of Germany, Mrs Eva Luise KÖhler

I sat next to the wonderful Avril Daly who is a Board Member of EURORDIS, Head of Public Affairs for the Irish Charity Fighting Blindness and a leading figure in the Irish rare disease community. We talked about CF in Ireland and the work of EURORDIS. Avril’s energy and commitment is incredible and she is a true inspiration. Others on my table were Ken O’Reilly and others from Biogen Idec and Axel Van Der Mersch who is a major funder of EURORDIS. 

Wednesday 27th 
EURORDIS “Round Table of Companies”:  Improving Access to Orphan Medicinal Products

Yann Le Cam gave a presentation summarising the latest policy initiatives and emerging thinking around rare diseases in Europe. Key themes included:

Evidence of EMA flexibility: when it comes to new orphan drugs

Adaptive/Progressive Licensing: the idea that you could start off with a licence in respect of a small population after a small trial but then gather more data and do progressively larger studies to build the evidence base and get a progressively broader licence over time. This would mean a constant cycle of data and a need for regulators and payers to become more comfortable making decisions on less evidence (at least initially)

Progressive Pricing: as the indication expands, pricing comes down.

Clinical Trials: trials need to anticipate the need for much better therapeutic value demonstration (HTA).

Payers: will always have their own views but they should not re-open the science as assessed by EMA.

Marketing Authorisation: EMA and others should share more information, more quickly with HTAs and Payers.

Value: what is value in orphan drugs? Greater focus on value-added for patients, physicians, payers, pharma, society as a whole.

FDA/EMA collaboration: move towards stronger collaboration in terms of scientific advice, protocol assistance, trial design, regulatory processes.

The two key initiatives being sponsored by the European Commission, namely CAVOMP and MOCA, are designed to improve access to orphan medicines and treatments for rare diseases. The emphasis is on creating a more efficient market and creating real value for all parties rather than thinking about the issues in terms of Corporate Social Responsibility which has been shown to be ineffective.

“CAVOMP”: Improving Informed Decisions Based on the Clinical Added Value of Orphan Medicinal Products

This is essentially a proposed methodology for removing duplication of work and sharing information more effectively (among regulators, national competent authorities, HTAs, payers, patient groups, clinicians, et al.) through the whole lifecycle of a new drug (Orphan Designation – Protocol Assistance – CHMP Opinion – Marketing Authorisation – HTA – Reimbursement). A key part of this is a permanent co-operation mechanism for HTAs building on the EUnetHTA. EUnetHTA is a network of government appointed organisations (from EU Member States, EEA and Accession countries) and a large number of relevant regional agencies and non-for-profit organisations that produce or contribute to HTA in Europe. See: http://www.eunethta.eu/.

EUCERD made a formal recommendation to the EC in September 2012 and the EC is considering how to implement it and incorporate it into future policy.

“MOCA”: Mechanism of Coordinated Access to Orphan Medicinal Products

The objective of this work is to find common, non-regulatory approaches to ensure better, timely and equitable access to orphan medicines after their marketing authorisation.

A key aspect is better identifying the true value of new orphan drugs and moving to a pricing system based on value rather than cost. While it is acknowledged that payers will want visibility on cost construction as a quid pro quo for market exclusivity, there is a need to move towards a more rational value-based approach. This is called the Transparent Value Framework (“TVF”).

The main criteria under discussion as part of the TVF are:
a) Availability of alternative treatments / unmet medical need;
b) Relative effectiveness (clinical improvement, QoL, etc. vs side-effects) and societal impact;
c) Response rate; and
d) Certainty of evidence.

I took part in a "breakout” session to talk about this and I raised some points about the burden of treatment in diseases like CF: a) that new treatments which reduce the burden of treatment and which are likely to have a positive impact on adherence (with potential associated savings for payers) should be valued more highly; and (b) that it is important for clinical trials to be designed in a way that provides HTA’s (and clinicians/patients) with the information they need to assess the benefits of new treatments in comparison to current standard of care as it exists in reality rather than as perceived by the FDA / EMA. These points were well received, people felt they were relevant to rare diseases generally and a number of people came up to me afterwards to say what a useful discussion it was and that they were keen to talk more.  

The final report is due in March 2013 and the EC will consider how best to implement the proposals and how to factor them into future policy.

Research also shows a great inequality of access to medicines amongst Member States (particularly in the countries suffering financial hardship) and major inequalities in pricing. For example, the Czech Republic pays more for medicines than the UK.  As a result of “reference pricing” where certain countries in the EU insist on paying the same as certain other countries in the EU system (even if they are in financial distress and benefiting from special deals with Pharma), there is now a tendency for Pharma to refuse to supply certain markets so as to protect pricing power in other more important markets. There are discussions going on as part of the MOCA process around mechanisms to improve equality in these areas. “Differential Pricing” is seen by all (including Pharma) as a viable option. This would involve countries in the EU with lower GDP/capita being charged lower prices.

The other topic of the day was “National Measures”. Each Member State has been told to develop a national plan for the treatment of rare diseases and this includes improving access to new orphan medicines. A few countries have implemented their plans, notably France, some have developed but not yet implemented (e.g. UK) and others are still developing.

Another topic discussed at various points was the concept of the “right to reimbursement” and free movement within the EU. In other words, rare disease patients resident in one country should be free to travel to other countries in the EU and be entitled to the same level of treatment. This is seen as an important long term objective. There are increasingly cases of people travelling or even moving to places where they can get treatment which is not available in their home markets and even cases where parents of children with rare diseases cannot afford to move to a new country so they put the child up for adoption to go to families living in countries where treatment is available. France absorbs a lot of patients in this way and it is seen as a major issue in terms of equality and sustainability.

Eurordis will be making all the presentations and other materials available on their website in due course. A huge amount of ground was covered in much more detail than I go into here but I hope this gives a flavour of everything.

This is a great community of people. I had expected it to be a lot of hot air and grand talk of unrealistic ambitions but I was surprised at the level of camaraderie and the way people were cutting through to practical issues. It was also very striking how everyone from the EC, MEPs, Pharma and Patient Groups were genuinely collaborating with a shared goal of getting medicines to patients faster. It was quite inspiring and definitely something to build on. 

In addition to the brilliant team at EURORDIS, I met people from the European Commission, European Medicines Agency’s Committee for Orphan Medicinal Products, Fighting Blindness, Alliances Maladies Rare, the European Network for Ichthyosis, the Belgian National Health Insurance System and the following Pharma companies: PTC Therapeutics, Pfizer, Genzyme, BioMarin Europe, Bioden Idec and Celgene.

I attended these events as a representative of the CF Trust and I would like to thank them for part-funding my trip.